Akiram Therapeutics

News

Akiram & ITM sign supply agreement for Lutetium-177 to support development of targeted antibody-radionuclide conjugate AKIR001 in solid tumours.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.